Top

BMC Cancer

Published in:

01-12-2021 | Hepatitis | Research article

Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma

Authors: Jian-Yao Wang, Xiang-Kun Wang, Guang-Zhi Zhu, Xin Zhou, Jun Yao, Xiao-Peng Ma, Bin Wang, Tao Peng

Published in: BMC Cancer | Issue 1/2021

Abstract

Backgroud

In our current work, we aimed to investigate the expressions of glypican (GPC) family genes at the mRNA level and assess their prognostic significances in patients with hepatocellular carcinoma (HCC).

Methods

The pathological roles of GPC family genes were examined using bioinformatics analysis. The diagnostic values of GPC genes were explored with the Gene Expression Profiling Interactive Analysis. Moreover, the mRNA expression and prognostic values of GPC genes were assessed via the KM plotter database.

Results

Our data showed that the expression of GPC-3 was dramatically increased in the liver tumor tissue. Moreover, the expressions of the other five GPC family members were not significantly different between the tumor and normal liver tissues (P > 0.05). Furthermore, the up-regulation of GPC-1 at the mRNA level was dramatically correlated to the reduced overall survival (OS) for all HCC patients (hazard ratio = 2.03, 95% confidence intervals =1.44–2.87, P = 4.1e-05) compared with its low-expression group. Besides, the prognosis of the Caucasians was related to most GPC family genes, while the prognosis of the Asian race was only related to the expression of GPC-2. Besides, for pathological factors, including stage, grade, AJCC, and vascular invasion, the higher the pathological grade and vascular invasiveness, the lower the expression levels of GPC family genes (P < 0.05). Finally, the expression levels of GPC-1, 2, and 3 in the hepatitis group were related to the poor prognosis of HCC in the risk factor (alcohol consumption and hepatitis) subgroup (P < 0.05).

Conclusions

Our findings indicated that GPC-3 was dysregulated in HCC compared with paracancerous tissues. The expression of GPC-1 could be used as a potent predictive index for the general prognosis of HCC. The pathology, patients, and risk factors might affect the prognostic value of GPC family genes in HCC.

Available only for authorised users

Torbenson M. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Hum Pathol. 2020. https://doi.org/10.1016/j.humpath.2020.12.009.

Singal A, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–61. https://doi.org/10.1016/j.jhep.2019.08.025.CrossRefPubMedPubMedCentral

Li N, Spetz M, Ho M. The role of Glypicans in cancer progression and therapy. J Histochem Cytochem. 2020;68(12):841–62. https://doi.org/10.1369/0022155420933709.CrossRefPubMedPubMedCentral

Kaur S, Cummings B. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;168:108–18. https://doi.org/10.1016/j.bcp.2019.06.020.CrossRefPubMed

Li N, Gao W, Zhang Y, Ho M. Glypicans as cancer therapeutic targets. Trends Cancer. 2018;4(11):741–54. https://doi.org/10.1016/j.trecan.2018.09.004.CrossRefPubMedPubMedCentral

Xu D, Su C, Sun L, Gao Y, Li Y. Performance of serum Glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis. Ann Hepatol. 2019;18(1):58–67. https://doi.org/10.5604/01.3001.0012.7863.CrossRefPubMed

Zhang J, Zhang M, Ma H, Song X, He L, Ye X, et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis. Medicine. 2018;97(24):e11130. https://doi.org/10.1097/MD.0000000000011130.CrossRefPubMedPubMedCentral

De Robertis M, Arigoni M, Loiacono L, Riccardo F, Calogero R, Feodorova Y, et al. Novel insights into notum and glypicans regulation in colorectal cancer. Oncotarget. 2015;6(38):41237–57. https://doi.org/10.18632/oncotarget.5652.CrossRefPubMedPubMedCentral

Li Y, Li M, Shats I, Krahn J, Flake G, Umbach D, et al. Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma. PLoS One. 2019;14(6):e0218067. https://doi.org/10.1371/journal.pone.0218067.CrossRefPubMedPubMedCentral

10.

Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10573–83. https://doi.org/10.3748/wjg.v21.i37.10573.CrossRefPubMedPubMedCentral

11.

da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef

12.

Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. https://doi.org/10.1093/nar/gkn923.CrossRef

13.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. https://doi.org/10.1038/nprot.2008.211.CrossRef

14.

Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–20.CrossRefPubMedPubMedCentral

15.

Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, et al. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26(22):2927–8. https://doi.org/10.1093/bioinformatics/btq562.CrossRefPubMedPubMedCentral

16.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

17.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613. https://doi.org/10.1093/nar/gky1131.CrossRefPubMed

18.

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

20.

Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–5.CrossRef

21.

Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006. https://doi.org/10.1098/rsos.181006.CrossRefPubMedPubMedCentral

22.

Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006. https://doi.org/10.1098/rsos.181006.CrossRefPubMedPubMedCentral

23.

Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease. 2019;30(2):193–200. https://doi.org/10.1007/s13337-019-00517-6.CrossRefPubMedPubMedCentral

24.

Pan C, Wang X, Chen W, Tao C, Xu X, Jin L, et al. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software. Med Oncol (Northwood, London, England). 2015;32(1):359.CrossRef

25.

Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012;18(19):2408–14. https://doi.org/10.3748/wjg.v18.i19.2408.CrossRefPubMedPubMedCentral

26.

Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19(Suppl 3):S455–63.CrossRefPubMed

27.

Yao M, Wang L, Fang M, Zheng W, Dong Z, Yao D. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. Biosci Trends. 2016;10(5):337–43. https://doi.org/10.5582/bst.2016.01176.CrossRefPubMed

28.

Fico A, Maina F, Dono R. Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci. 2011;68(6):923–9. https://doi.org/10.1007/s00018-007-7471-6.CrossRefPubMed

29.

Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer (Oxford, England : 1990). 2011;47(3):333–8.CrossRef

30.

Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005;280(3):2116–25. https://doi.org/10.1074/jbc.M410090200.CrossRefPubMed

31.

Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development (Cambridge, England). 2004;131(24):6009–21.CrossRef

32.

Wang S, Qiu Y, Bai B. The expression, regulation, and biomarker potential of Glypican-1 in cancer. Front Oncol. 2019;9:614. https://doi.org/10.3389/fonc.2019.00614.CrossRefPubMedPubMedCentral

33.

Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001;61(14):5562–9.PubMed

34.

Qian JY, Tan YL, Zhang Y, Yang YF, Li XQ. Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy. Oncol Lett. 2018;16(1):1253–8. https://doi.org/10.3892/ol.2018.8701.CrossRefPubMedPubMedCentral

35.

Xiao D, Dong Z, Zhen L, Xia G, Huang X, Wang T, et al. Combined Exosomal GPC1, CD82, and serum CA19-9 as multiplex targets: a specific, sensitive, and reproducible detection panel for the diagnosis of pancreatic cancer. Mol Cancer Res. 2020;18(2):300–10. https://doi.org/10.1158/1541-7786.MCR-19-0588.CrossRefPubMed

36.

Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting Glypican-3. Front Oncol. 2019;9:248. https://doi.org/10.3389/fonc.2019.00248.CrossRefPubMedPubMedCentral

37.

Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129(6):899–906. https://doi.org/10.1309/HCQWPWD50XHD2DW6.CrossRefPubMed

38.

De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol. 2003;163(3):625–35. https://doi.org/10.1083/jcb.200302152.CrossRefPubMedPubMedCentral

39.

Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers. 2019;11(9):1139. https://doi.org/10.3390/cancers11091339.

40.

Ortiz MV, Roberts SS, Glade Bender J, Shukla N, Wexler LH. Immunotherapeutic targeting of GPC3 in pediatric solid Embryonal tumors. Front Oncol. 2019;9:108. https://doi.org/10.3389/fonc.2019.00108.CrossRefPubMedPubMedCentral

41.

Jeon Y, Kim H, Jang ES, Hong S, Kim JW, Yoon YS, et al. Expression profile and prognostic value of glypican-3 in post-operative south Korean hepatocellular carcinoma patients. APMIS Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2016;124(3):208–15. https://doi.org/10.1111/apm.12491.CrossRefPubMed

42.

Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol. 2014;49(1):117–25. https://doi.org/10.1007/s00535-013-0793-2.CrossRefPubMed

43.

Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci U S A. 2017;114(32):E6623–e6631. https://doi.org/10.1073/pnas.1706055114.CrossRefPubMedPubMedCentral

44.

Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol. 2012;2:194.PubMedPubMedCentral

45.

Xu N, Wu YP, Yin HB, Xue XY, Gou X. Molecular network-based identification of competing endogenous RNAs and mRNA signatures that predict survival in prostate cancer. J Transl Med. 2018;16(1):274. https://doi.org/10.1186/s12967-018-1637-x.CrossRefPubMedPubMedCentral

46.

Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, et al. Identification of GPC2 as an Oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell. 2017;32(3):295–309.e212.CrossRefPubMedPubMedCentral

47.

Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol. 2005;6(7):530–41. https://doi.org/10.1038/nrm1681.CrossRefPubMed

48.

De Cat B, David G. Developmental roles of the glypicans. Semin Cell Dev Biol. 2001;12(2):117–25. https://doi.org/10.1006/scdb.2000.0240.CrossRefPubMed

49.

Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics. 1997;40(1):24–30. https://doi.org/10.1006/geno.1996.4518.CrossRefPubMed

50.

Liu T, Zhang X, Sha K, Liu X, Zhang L. Wang B: miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5. Cell Prolif. 2015;48(3):330–7. https://doi.org/10.1111/cpr.12181.CrossRefPubMedPubMedCentral

51.

Hong X, Zhang Z, Pan L, Ma W, Zhai X, Gu C, et al. MicroRNA-301b promotes the proliferation and invasion of glioma cells through enhancing activation of Wnt/β-catenin signaling via targeting Glypican-5. Eur J Pharmacol. 2019;854:39–47. https://doi.org/10.1016/j.ejphar.2019.03.057.CrossRefPubMed

52.

Cao J, Ma J, Sun L, Li J, Qin T, Zhou C, et al. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. J Cell Biochem. 2018;119(11):9498–512. https://doi.org/10.1002/jcb.27266.CrossRefPubMed

53.

Zhao D, Liu S, Sun L, Zhao Z, Liu S, Kuang X, et al. Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma. Virus Res. 2016;220:52–6. https://doi.org/10.1016/j.virusres.2016.04.005.CrossRefPubMed

54.

Veugelers M, De Cat B, Ceulemans H, Bruystens AM, Coomans C, Dürr J, et al. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans. J Biol Chem. 1999;274(38):26968–77. https://doi.org/10.1074/jbc.274.38.26968.CrossRefPubMed

55.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, et al. Overexpression of GPC6 and TMEM132D in early stage ovarian cancer correlates with CD8+ T-lymphocyte infiltration and increased patient survival. Biomed Res Int. 2015;2015:712438.CrossRefPubMedPubMedCentral

56.

Fan C, Tu C, Qi P, Guo C, Xiang B, Zhou M, et al. GPC6 promotes cell proliferation, migration, and invasion in nasopharyngeal carcinoma. J Cancer. 2019;10(17):3926–32. https://doi.org/10.7150/jca.31345.CrossRefPubMedPubMedCentral

Title: Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma
Authors: Jian-Yao Wang
Xiang-Kun Wang
Guang-Zhi Zhu
Xin Zhou
Jun Yao
Xiao-Peng Ma
Bin Wang
Tao Peng
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatitis
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08104-z

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Backgroud

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer

Remote interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review and meta-analysis

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer

Clinicopathological features and outcomes in gastric-type of HPV-independent endocervical adenocarcinomas

Descriptive epidemiology of nasopharyngeal carcinoma at Tikur Anbessa Hospital, Ethiopia